Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Microdeletion syndromes (chromosomes 1 to 11)

Carlos A Bacino, MD, FACMG
Section Editor
Helen V Firth, DM, FRCP, DCH
Deputy Editor
Elizabeth TePas, MD, MS


Chromosome deletions that span at least five megabases (Mb) are usually microscopically visible on chromosome banded karyotypes. Microdeletions, or submicroscopic deletions, are chromosomal deletions that are too small to be detected by light microscopy using conventional cytogenetic methods. Specialized testing is needed to identify these deletions. Microdeletions are typically one to three Mb long and involve several contiguous genes. The exact size and location of a microdeletion that causes a syndrome may vary, but a specific "critical region" is consistently involved. Most phenotypic effects of these microdeletions are due to haploinsufficiency of a few critical genes or, in some cases, a single gene.

This topic reviews microdeletion syndromes involving chromosomes 1 through 11. Microdeletion syndromes involving chromosomes 12 through 22 are discussed separately, as are microduplication syndromes and congenital abnormalities of the sex chromosomes. Other congenital chromosomal abnormalities, such as trisomies, are also reviewed in detail elsewhere. (See "Microdeletion syndromes (chromosomes 12 to 22)" and "Microduplication syndromes" and "Sex chromosome abnormalities" and "Congenital cytogenetic abnormalities".)


Genomic disorders are diseases that result from the loss or gain of chromosomal/DNA material. The most common and better delineated genomic disorders are divided in two main categories: those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes). (See "Genomic disorders: An overview".)

Copy number variations (CNVs) are submicroscopic genomic differences in the number of copies of one or more sections of DNA that result in DNA gains or losses (figure 1). Some CNVs are pathogenic and cause syndromic disorders with consistent phenotypic features, as are discussed here. Other CNVs are associated with disease susceptibility or resistance, and the same CNVs can be associated with several diverse disorders. Still other CNVs are part of normal genetic variation and have no recognized disease association. Contiguous gene syndromes can occur when CNVs affect several adjacent genes. (See "Overview of genetic variation", section on 'Copy number variations (CNVs)' and "Basic principles of genetic disease", section on 'Copy number variation'.)

The main mechanism leading to disease in genomic disorders is a change in the copy number of a dose-sensitive gene or genes due to a deletion or duplication. This disrupts the gene(s) and alters the amount of protein produced. Other disease mechanisms include uncovering of recessive disorders, disruption of imprinted genes, and regulatory elements outside genes. (See "Genomic disorders: An overview", section on 'Disease mechanisms'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Sep 29, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Battaglia A, Hoyme HE, Dallapiccola B, et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics 2008; 121:404.
  2. Gajecka M, Mackay KL, Shaffer LG. Monosomy 1p36 deletion syndrome. Am J Med Genet C Semin Med Genet 2007; 145C:346.
  3. Heilstedt HA, Ballif BC, Howard LA, et al. Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. Am J Hum Genet 2003; 72:1200.
  4. Shapira SK, McCaskill C, Northrup H, et al. Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am J Hum Genet 1997; 61:642.
  5. GeneReviews: 1p36 Deletion Syndrome. http://www.ncbi.nlm.nih.gov/books/NBK1191/ (Accessed on December 21, 2011).
  6. Genetics Home Reference: 1p36 deletion syndrome. http://ghr.nlm.nih.gov/condition/1p36-deletion-syndrome (Accessed on December 21, 2011).
  7. Buck A, du Souich C, Boerkoel CF. Minimal genotype--phenotype correlation for small deletions within distal 1p36. Am J Med Genet A 2011; 155A:3164.
  8. Brunetti-Pierri N, Berg JS, Scaglia F, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 2008; 40:1466.
  9. Mefford HC, Sharp AJ, Baker C, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008; 359:1685.
  10. GeneReviews: 1q21.1 Microdeletion. http://www.ncbi.nlm.nih.gov/books/NBK52787/ (Accessed on December 29, 2011).
  11. GeneReviews: Thrombocytopenia Absent Radius syndrome http://www.ncbi.nlm.nih.gov/books/NBK23758/ (Accessed on December 29, 2011).
  12. Gounder DS, Pullon HW, Ockelford PA, Nicol RO. Clinical manifestations of the thrombocytopenia and absent radii (TAR) syndrome. Aust N Z J Med 1989; 19:479.
  13. Klopocki E, Schulze H, Strauss G, et al. Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome. Am J Hum Genet 2007; 80:232.
  14. Ward RE, Bixler D, Provisor AJ, Bader P. Parent to child transmission of the thrombocytopenia absent radius (TAR) syndrome. Am J Med Genet Suppl 1986; 2:207.
  15. Albers CA, Paul DS, Schulze H, et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet 2012; 44:435.
  16. Rajcan-Separovic E, Harvard C, Liu X, et al. Clinical and molecular cytogenetic characterisation of a newly recognised microdeletion syndrome involving 2p15-16.1. J Med Genet 2007; 44:269.
  17. Liu X, Malenfant P, Reesor C, et al. 2p15-p16.1 microdeletion syndrome: molecular characterization and association of the OTX1 and XPO1 genes with autism spectrum disorders. Eur J Hum Genet 2011; 19:1264.
  18. Jorgez CJ, Rosenfeld JA, Wilken NR, et al. Genitourinary defects associated with genomic deletions in 2p15 encompassing OTX1. PLoS One 2014; 9:e107028.
  19. Balci TB, Sawyer SL, Davila J, et al. Brain malformations in a patient with deletion 2p16.1: A refinement of the phenotype to BCL11A. Eur J Med Genet 2015; 58:351.
  20. Lévy J, Coussement A, Dupont C, et al. Molecular and clinical delineation of 2p15p16.1 microdeletion syndrome. Am J Med Genet A 2017; 173:2081.
  21. van Bon BW, Koolen DA, Brueton L, et al. The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype. Eur J Hum Genet 2010; 18:163.
  22. Talkowski ME, Mullegama SV, Rosenfeld JA, et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet 2011; 89:551.
  23. Mullegama SV, Alaimo JT, Chen L, Elsea SH. Phenotypic and molecular convergence of 2q23.1 deletion syndrome with other neurodevelopmental syndromes associated with autism spectrum disorder. Int J Mol Sci 2015; 16:7627.
  24. Mullegama SV, Elsea SH. Clinical and Molecular Aspects of MBD5-Associated Neurodevelopmental Disorder (MAND). Eur J Hum Genet 2016; 24:1235.
  25. GeneReviews: 2q37 Deletion Syndrome http://www.ncbi.nlm.nih.gov/books/NBK1158/ (Accessed on December 31, 2011).
  26. Falk RE, Casas KA. Chromosome 2q37 deletion: clinical and molecular aspects. Am J Med Genet C Semin Med Genet 2007; 145C:357.
  27. Galasso C, Lo-Castro A, Lalli C, et al. Deletion 2q37: an identifiable clinical syndrome with mental retardation and autism. J Child Neurol 2008; 23:802.
  28. Shrimpton AE, Braddock BR, Thomson LL, et al. Molecular delineation of deletions on 2q37.3 in three cases with an Albright hereditary osteodystrophy-like phenotype. Clin Genet 2004; 66:537.
  29. Williams SR, Aldred MA, Der Kaloustian VM, et al. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am J Hum Genet 2010; 87:219.
  30. Tassano E, Buttgereit J, Bader M, et al. Genotype-Phenotype Correlation of 2q37 Deletions Including NPPC Gene Associated with Skeletal Malformations. PLoS One 2013; 8:e66048.
  31. Tazelaar J, Roberson J, Van Dyke DL, et al. Mother and son with deletion of 3p25-pter. Am J Med Genet 1991; 39:130.
  32. Nienhaus H, Mau U, Zang KD. Infant with del(3) (p25-pter): karyotype-phenotype correlation and review of previously reported cases. Am J Med Genet 1992; 44:573.
  33. Drumheller T, McGillivray BC, Behrner D, et al. Precise localisation of 3p25 breakpoints in four patients with the 3p-syndrome. J Med Genet 1996; 33:842.
  34. Shuib S, McMullan D, Rattenberry E, et al. Microarray based analysis of 3p25-p26 deletions (3p- syndrome). Am J Med Genet A 2009; 149A:2099.
  35. Fernandez TV, García-González IJ, Mason CE, et al. Molecular characterization of a patient with 3p deletion syndrome and a review of the literature. Am J Med Genet A 2008; 146A:2746.
  36. Grozeva D, Carss K, Spasic-Boskovic O, et al. De novo loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. Am J Hum Genet 2014; 94:618.
  37. Kuechler A, Zink AM, Wieland T, et al. Loss-of-function variants of SETD5 cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome. Eur J Hum Genet 2015; 23:753.
  38. Ballif BC, Theisen A, Coppinger J, et al. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. Mol Cytogenet 2008; 1:8.
  39. Willatt L, Cox J, Barber J, et al. 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am J Hum Genet 2005; 77:154.
  40. Levinson DF, Duan J, Oh S, et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 2011; 168:302.
  41. Città S, Buono S, Greco D, et al. 3q29 microdeletion syndrome: Cognitive and behavioral phenotype in four patients. Am J Med Genet A 2013; 161A:3018.
  42. Sagar A, Bishop JR, Tessman DC, et al. Co-occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion. Am J Med Genet A 2013; 161A:845.
  43. Stewart LR, Hall AL, Kang SH, et al. High frequency of known copy number abnormalities and maternal duplication 15q11-q13 in patients with combined schizophrenia and epilepsy. BMC Med Genet 2011; 12:154.
  44. Quintero-Rivera F, Sharifi-Hannauer P, Martinez-Agosto JA. Autistic and psychiatric findings associated with the 3q29 microdeletion syndrome: case report and review. Am J Med Genet A 2010; 152A:2459.
  45. Clayton-Smith J, Giblin C, Smith RA, et al. Familial 3q29 microdeletion syndrome providing further evidence of involvement of the 3q29 region in bipolar disorder. Clin Dysmorphol 2010; 19:128.
  46. Glassford MR, Rosenfeld JA, Freedman AA, et al. Novel features of 3q29 deletion syndrome: Results from the 3q29 registry. Am J Med Genet A 2016; 170A:999.
  47. Estabrooks LL, Rao KW, Driscoll DA, et al. Preliminary phenotypic map of chromosome 4p16 based on 4p deletions. Am J Med Genet 1995; 57:581.
  48. Wright TJ, Ricke DO, Denison K, et al. A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region. Hum Mol Genet 1997; 6:317.
  49. Dallapiccola B, Mandich P, Bellone E, et al. Parental origin of chromosome 4p deletion in Wolf-Hirschhorn syndrome. Am J Med Genet 1993; 47:921.
  50. Battaglia A, Filippi T, Carey JC. Update on the clinical features and natural history of Wolf-Hirschhorn (4p-) syndrome: experience with 87 patients and recommendations for routine health supervision. Am J Med Genet C Semin Med Genet 2008; 148C:246.
  51. Nimura K, Ura K, Shiratori H, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009; 460:287.
  52. Hart L, Rauch A, Carr AM, et al. LETM1 haploinsufficiency causes mitochondrial defects in cells from humans with Wolf-Hirschhorn syndrome: implications for dissecting the underlying pathomechanisms in this condition. Dis Model Mech 2014; 7:535.
  53. Andersen EF, Carey JC, Earl DL, et al. Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome. Eur J Hum Genet 2014; 22:464.
  54. Zollino M, Murdolo M, Marangi G, et al. On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet 2008; 148C:257.
  55. Hanley-Lopez J, Estabrooks LL, Stiehm R. Antibody deficiency in Wolf-Hirschhorn syndrome. J Pediatr 1998; 133:141.
  56. Battaglia A, Carey JC, Cederholm P, et al. Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases. Pediatrics 1999; 103:830.
  57. Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002; 30:365.
  58. Kurotaki N, Stankiewicz P, Wakui K, et al. Sotos syndrome common deletion is mediated by directly oriented subunits within inverted Sos-REP low-copy repeats. Hum Mol Genet 2005; 14:535.
  59. Nagai T, Matsumoto N, Kurotaki N, et al. Sotos syndrome and haploinsufficiency of NSD1: clinical features of intragenic mutations and submicroscopic deletions. J Med Genet 2003; 40:285.
  60. Tatton-Brown K, Rahman N. The NSD1 and EZH2 overgrowth genes, similarities and differences. Am J Med Genet C Semin Med Genet 2013; 163C:86.
  61. Faravelli F. NSD1 mutations in Sotos syndrome. Am J Med Genet C Semin Med Genet 2005; 137C:24.
  62. Genetics Home Reference: Sotos syndrome. http://ghr.nlm.nih.gov/condition/sotos-syndrome (Accessed on December 21, 2011).
  63. GeneReviews: Sotos Syndrome. http://www.ncbi.nlm.nih.gov/books/NBK1479/ (Accessed on December 21, 2011).
  64. Le Caignec C, De Mas P, Vincent MC, et al. Subtelomeric 6p deletion: clinical, FISH, and array CGH characterization of two cases. Am J Med Genet A 2005; 132A:175.
  65. Maclean K, Smith J, St Heaps L, et al. Axenfeld-Rieger malformation and distinctive facial features: Clues to a recognizable 6p25 microdeletion syndrome. Am J Med Genet A 2005; 132A:381.
  66. Tonoki H, Harada N, Shimokawa O, et al. Axenfeld-Rieger anomaly and Axenfeld-Rieger syndrome: clinical, molecular-cytogenetic, and DNA array analyses of three patients with chromosomal defects at 6p25. Am J Med Genet A 2011; 155A:2925.
  67. DeScipio C. The 6p subtelomere deletion syndrome. Am J Med Genet C Semin Med Genet 2007; 145C:377.
  68. van der Knaap MS, Kriek M, Overweg-Plandsoen WC, et al. Cerebral white matter abnormalities in 6p25 deletion syndrome. AJNR Am J Neuroradiol 2006; 27:586.
  69. Alward WL. Axenfeld-Rieger syndrome in the age of molecular genetics. Am J Ophthalmol 2000; 130:107.
  70. Nishimura DY, Swiderski RE, Alward WL, et al. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet 1998; 19:140.
  71. Smith RS, Zabaleta A, Kume T, et al. Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development. Hum Mol Genet 2000; 9:1021.
  72. Delahaye A, Khung-Savatovsky S, Aboura A, et al. Pre- and postnatal phenotype of 6p25 deletions involving the FOXC1 gene. Am J Med Genet A 2012; 158A:2430.
  73. Morris CA. Introduction: Williams syndrome. Am J Med Genet C Semin Med Genet 2010; 154C:203.
  74. GeneReviews: Williams Syndrome. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/books/NBK1249/ (Accessed on February 15, 2012).
  75. Francke U. Williams-Beuren syndrome: genes and mechanisms. Hum Mol Genet 1999; 8:1947.
  76. Marler JA, Sitcovsky JL, Mervis CB, et al. Auditory function and hearing loss in children and adults with Williams syndrome: cochlear impairment in individuals with otherwise normal hearing. Am J Med Genet C Semin Med Genet 2010; 154C:249.
  77. Barozzi S, Soi D, Comiotto E, et al. Audiological findings in Williams syndrome: a study of 69 patients. Am J Med Genet A 2012; 158A:759.
  78. Pober BR. Williams-Beuren syndrome. N Engl J Med 2010; 362:239.
  79. Sakurai T, Dorr NP, Takahashi N, et al. Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions. Autism Res 2011; 4:28.
  80. Mervis CB, John AE. Cognitive and behavioral characteristics of children with Williams syndrome: implications for intervention approaches. Am J Med Genet C Semin Med Genet 2010; 154C:229.
  81. Teebi AS. Nablus mask-like facial syndrome. Am J Med Genet 2000; 95:407.
  82. Raas-Rothschild A, Dijkhuizen T, Sikkema-Raddatz B, et al. The 8q22.1 microdeletion syndrome or Nablus mask-like facial syndrome: report on two patients and review of the literature. Eur J Med Genet 2009; 52:140.
  83. Shieh JT, Aradhya S, Novelli A, et al. Nablus mask-like facial syndrome is caused by a microdeletion of 8q detected by array-based comparative genomic hybridization. Am J Med Genet A 2006; 140:1267.
  84. Jain S, Yang P, Farrell SA. A case of 8q22.1 microdeletion without the Nablus mask-like facial syndrome phenotype. Eur J Med Genet 2010; 53:108.
  85. Hall BD, Langer LO, Giedion A, et al. Langer-Giedion syndrome. Birth Defects Orig Artic Ser 1974; 10:147.
  86. Bowen P, Biederman B, Hoo JJ. The critical segment for the Langer-Giedion syndrome: 8q24.11----q24.12. Ann Genet 1985; 28:224.
  87. Parrish JE, Wagner MJ, Hecht JT, et al. Molecular analysis of overlapping chromosomal deletions in patients with Langer-Giedion syndrome. Genomics 1991; 11:54.
  88. Wilson WG, Herrington RT, Aylsworth AS. The Langer-Giedion syndrome: report of a 22-year old woman. Pediatrics 1979; 64:542.
  89. Carvalho DR, Santos SC, Oliveira MD, Speck-Martins CE. Tibial hemimelia in Langer-Giedion syndrome with 8q23.1-q24.12 interstitial deletion. Am J Med Genet A 2011; 155A:2784.
  90. Momeni P, Glöckner G, Schmidt O, et al. Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I. Nat Genet 2000; 24:71.
  91. Jones KL. Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006.
  92. Alfi O, Donnell GN, Crandall BF, et al. Deletion of the short arm of chromosome no.9 (46,9p-): a new deletion syndrome. Ann Genet 1973; 16:17.
  93. Christ LA, Crowe CA, Micale MA, et al. Chromosome breakage hotspots and delineation of the critical region for the 9p-deletion syndrome. Am J Hum Genet 1999; 65:1387.
  94. Swinkels ME, Simons A, Smeets DF, et al. Clinical and cytogenetic characterization of 13 Dutch patients with deletion 9p syndrome: Delineation of the critical region for a consensus phenotype. Am J Med Genet A 2008; 146A:1430.
  95. Harada N, Visser R, Dawson A, et al. A 1-Mb critical region in six patients with 9q34.3 terminal deletion syndrome. J Hum Genet 2004; 49:440.
  96. Stewart DR, Huang A, Faravelli F, et al. Subtelomeric deletions of chromosome 9q: a novel microdeletion syndrome. Am J Med Genet A 2004; 128A:340.
  97. Verhoeven WM, Egger JI, Vermeulen K, et al. Kleefstra syndrome in three adult patients: further delineation of the behavioral and neurological phenotype shows aspects of a neurodegenerative course. Am J Med Genet A 2011; 155A:2409.
  98. Stewart DR, Kleefstra T. The chromosome 9q subtelomere deletion syndrome. Am J Med Genet C Semin Med Genet 2007; 145C:383.
  99. Kleefstra T, van Zelst-Stams WA, Nillesen WM, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet 2009; 46:598.
  100. Genetics Home Reference: Kleefstra syndrome. http://ghr.nlm.nih.gov/condition/kleefstra-syndrome (Accessed on January 03, 2012).
  101. Greenberg F, Valdes C, Rosenblatt HM, et al. Hypoparathyroidism and T cell immune defect in a patient with 10p deletion syndrome. J Pediatr 1986; 109:489.
  102. Monaco G, Pignata C, Rossi E, et al. DiGeorge anomaly associated with 10p deletion. Am J Med Genet 1991; 39:215.
  103. Obregon MG, Mingarelli R, Giannotti A, et al. Partial deletion 10p syndrome. Report of two patients. Ann Genet 1992; 35:101.
  104. Schuffenhauer S, Seidel H, Oechsler H, et al. DiGeorge syndrome and partial monosomy 10p: case report and review. Ann Genet 1995; 38:162.
  105. Shapira M, Borochowitz Z, Bar-El H, et al. Deletion of the short arm of chromosome 10 (10p13): report of a patient and review. Am J Med Genet 1994; 52:34.
  106. Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000; 406:419.
  107. Brémond-Gignac D, Crolla JA, Copin H, et al. Combination of WAGR and Potocki-Shaffer contiguous deletion syndromes in a patient with an 11p11.2-p14 deletion. Eur J Hum Genet 2005; 13:409.
  108. GeneReviews: Wilms Tumor Overview. http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK1294/ (Accessed on April 08, 2014).
  109. Chien WH, Sue WC, Kuo PL, et al. Potocki-Shaffer syndrome: report of one case. Acta Paediatr Taiwan 2003; 44:242.
  110. Romeike BF, Wuyts W. Proximal chromosome 11p contiguous gene deletion syndrome phenotype: case report and review of the literature. Clin Neuropathol 2007; 26:1.
  111. Hall CR, Wu Y, Shaffer LG, Hecht JT. Familial case of Potocki-Shaffer syndrome associated with microdeletion of EXT2 and ALX4. Clin Genet 2001; 60:356.
  112. Wu YQ, Badano JL, McCaskill C, et al. Haploinsufficiency of ALX4 as a potential cause of parietal foramina in the 11p11.2 contiguous gene-deletion syndrome. Am J Hum Genet 2000; 67:1327.
  113. Kim HG, Kim HT, Leach NT, et al. Translocations disrupting PHF21A in the Potocki-Shaffer-syndrome region are associated with intellectual disability and craniofacial anomalies. Am J Hum Genet 2012; 91:56.
  114. Swarr DT, Bloom D, Lewis RA, et al. Potocki-Shaffer syndrome: comprehensive clinical assessment, review of the literature, and proposals for medical management. Am J Med Genet A 2010; 152A:565.
  115. Favier R, Jondeau K, Boutard P, et al. Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. Thromb Haemost 2003; 90:893.
  116. Grossfeld PD, Mattina T, Lai Z, et al. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet A 2004; 129A:51.
  117. Vo KK, Jarocha DJ, Lyde RB, et al. FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology. Blood 2017; 129:3486.
  118. Akshoomoff N, Mattson SN, Grossfeld PD. Evidence for autism spectrum disorder in Jacobsen syndrome: identification of a candidate gene in distal 11q. Genet Med 2015; 17:143.
  119. Tyson C, Qiao Y, Harvard C, et al. Submicroscopic deletions of 11q24-25 in individuals without Jacobsen syndrome: re-examination of the critical region by high-resolution array-CGH. Mol Cytogenet 2008; 1:23.